

SCIENCE OF
POSSIBILITY
At Vertex, we invest in scientific innovation to create transformative medicines for people with serious diseases.
Vertex and CRISPR Tx present new data at EHA 2022 on investigational gene-edited therapy for the treatment of sickle cell...
Our investigational medicine for the potential treatment of APOL1-mediated kidney disease receives two regulatory designations
Vertex presents new data on Phase 1/2 clinical trial for type 1 diabetes at American Diabetes Association Scientific Sessions Conference
View our 2021 Corporate Responsibility Report
Vertex announces that the U.S. FDA has lifted the clinical hold on the Phase 1/2 clinical trial for the potential treatment of type 1 diabetes.
Working at Vertex
Working at Vertex
Our company is built on an inclusive culture that brings together the best and brightest in every field striving for one goal: to improve the lives of people with serious diseases.

Featured Stories